Skin Tissue Engineering-In Vivo and In Vitro Applications

Clinics in Plastic Surgery

Volumn 39, Issue 1, 2012, Pages 33-58

  Groeber, Florian ^a,b   Holeiter, Monika ^a,c   Hampel, Martina ^a,b   Hinderer, Svenja ^a,c   Schenke Layland, Katja ^a,c  

^a FRAUNHOFER INSTITUTE FOR INTERFACIAL ENGINEERING AND BIOTECHNOLOGY IGB   (Germany)

^b UNIVERSITY OF STUTTGART   (Germany)

^c UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Extracellular matrix; In vitro models; Keratinocytes; Melanocytes; Skin; Tissue engineering

Indexed keywords

RAPAMYCIN;

AUTOTRANSPLANTATION; BURN; CANDIDA ALBICANS; CANDIDIASIS; DERMIS; EPIDERMIS; FULL THICKNESS SKIN GRAFT; GRAFT SURVIVAL; HERPES SIMPLEX; HUMAN; HUMAN VERSUS ANIMAL COMPARISON; IN VITRO STUDY; IN VIVO STUDY; INFECTION RISK; MELANOMA; NONHUMAN; PSORIASIS; REVIEW; SKIN ALLOGRAFT; SKIN AUTOGRAFT; SKIN FIBROBLAST; SKIN PROTECTION; SKIN TRANSPLANTATION; TISSUE ENGINEERING; VIRUS TRANSMISSION; WOUND HEALING;

EID: 81455132645     PISSN: 00941298     EISSN: 15580504     Source Type: Journal    
DOI: 10.1016/j.cps.2011.09.007     Document Type: Review

References (204)

1. MacNeil S. Progress and opportunities for tissue-engineered skin. Nature 2007, 445:874-880.
2. Ponec M. Skin constructs for replacement of skin tissues for in vitro testing. Adv Drug Deliv Rev 2002, 54(Suppl 1):S19-S30.
3. Vacanti C.A., Mikos A.G. Tissue Eng 1995, 1:1-2.
4. Falkenberg F.W., Weichert H., Krane M., et al. In vitro production of monoclonal antibodies in high concentration in a new and easy to handle modular minifermenter. J Immunol Meth 1995, 179:13-29.
5. Schade R., Pfister C., Halatsch R., et al. Polyclonal IgY Antibodies from Chicken Egg Yolk-An Alternative to the Production of Mammalian IgG type Antibodies in Rabbits. Fund for the Replacement of Animals in Medical Experiments 1991, 403-419. ATLA, Nottingham.
6. Midwood K.S., Williams L.V., Schwarzbauer J.E. Tissue repair and the dynamics of the extracellular matrix. Int J Biochem Cell Biol 2004, 36:1031-1037.
7. Diegelmann R.F., Evans M.C. Wound healing: an overview of acute, fibrotic and delayed healing. Front Biosci 2004, 9:283-289.
8. Papini R. Management of burn injuries of various depths. BMJ 2004, 329:158-160.
9. Blanpain C., Lowry W.E., Geoghegan A., et al. Self-renewal, multipotency, and the existence of two cell populations within an epithelial stem cell niche. Cell 2004, 118:635-648.
10. Tumbar T. Epithelial skin stem cells. Meth. Enzymol 2006, 419:73-99.
11. Tumbar T., Guasch G., Greco V., et al. Defining the epithelial stem cell niche in skin. Science 2004, 303:359-363.
12. Shevchenko R.V., James S.L., James S.E. A review of tissue-engineered skin bioconstructs available for skin reconstruction. J R Soc Interface 2010, 7:229-258.
13. Herndon D.N., Barrow R.E., Rutan R.L., et al. A comparison of conservative versus early excision. Therapies in severely burned patients. Ann Surg 1989, 209:547-552. [discussion: 552-543].
14. Stanton R.A., Billmire D.A. Skin resurfacing for the burned patient. Clin Plast Surg 2002, 29:29-51.
15. Andreassi A., Bilenchi R., Biagioli M., et al. Classification and pathophysiology of skin grafts. Clin Dermatol 2005, 23:332-337.
16. Zilberman M., Elsner J.J. Antibiotic-eluting medical devices for various applications. J Control Release 2008, 130:202-215.
17. Vindenes H., Bjerknes R. Activation of polymorphonuclear neutrophilic granulocytes following burn injury: alteration of Fc-receptor and complement-receptor expression and of opsonophagocytosis. J Trauma 1994, 36:161-167.
18. Yamamoto H., Siltharm S., deSerres S., et al. Effect of cyclo-oxygenase inhibition on in vitro B-cell function after burn injury. J Trauma 1996, 41:612-619. [discussion: 620-611].
19. Converse J.M., Smahel J., Ballantyne D.L., et al. Inosculation of vessels of skin graft and host bed: a fortuitous encounter. Br J Plast Surg 1975, 28:274-282.
20. Rose J.K., Herndon D.N. Advances in the treatment of burn patients. Burns 1997, 23(Suppl 1):S19-S26.
21. Fratianne R.B., Brandt C.P. Improved survival of adults with extensive burns. J Burn Care Rehabil 1997, 18:347-351.
22. Wolfe R.A., Roi L.D., Flora J.D., et al. Mortality differences and speed of wound closure among specialized burn care facilities. JAMA 1983, 250:763-766.
23. Quinby W.C., Burke J.F., Bondoc C.C. Primary excision and immediate wound closure. Intensive Care Med 1981, 7:71-76.
24. Eisenbud D., Huang N.F., Luke S., et al. Skin substitutes and wound healing: current status and challenges. Wounds 2004, 16:2-17.
25. Hansen S.L., Voigt D.W., Wiebelhaus P., et al. Using skin replacement products to treat burns and wounds. Adv Skin Wound Care 2001, 14:37-44. [quiz: 45-36].
26. Waymack P., Duff R.G., Sabolinski M. The effect of a tissue engineered bilayered living skin analog, over meshed split-thickness autografts on the healing of excised burn wounds. The Apligraf Burn Study Group. Burns 2000, 26:609-619.
27. Hansbrough J.F., Mozingo D.W., Kealey G.P., et al. Clinical trials of a biosynthetic temporary skin replacement, Dermagraft-Transitional Covering, compared with cryopreserved human cadaver skin for temporary coverage of excised burn wounds. J Burn Care Rehabil 1997, 18:43-51.
28. Pham C., Greenwood J., Cleland H., et al. Bioengineered skin substitutes for the management of burns: a systematic review. Burns 2007, 33:946-957.
29. Khachemoune A., Bello Y.M., Phillips T.J. Factors that influence healing in chronic venous ulcers treated with cryopreserved human epidermal cultures. Dermatol Surg 2002, 28:274-280.
30. Alvarez-Diaz C., Cuenca-Pardo J., Sossa-Serrano A. Burns treated with frozen cultured human allogeneic epidermal sheets. J Burn Care Rehabil 2000, 21:291-299.
31. Bolivar-Flores Y.J., Kuri-Harcuch W. Frozen allogeneic human epidermal cultured sheets for the cure of complicated leg ulcers. Dermatol Surg 1999, 25:610-617.
32. Rheinwald J.G., Green H. Serial cultivation of strains of human epidermal keratinocytes: the formation of keratinizing colonies from single cells. Cell 1975, 6:331-343.
33. Bolivar-Flores J., Poumian E., Marsch-Moreno M., et al. Use of cultured human epidermal keratinocytes for allografting burns and conditions for temporary banking of the cultured allografts. Burns 1990, 16:3-8.
34. Duinslaeger L.A., Verbeken G., Vanhalle S., et al. Cultured allogeneic keratinocyte sheets accelerate healing compared to Op-site treatment of donor sites in burns. J Burn Care Rehabil 1997, 18:545-551.
35. Madden M.R., LaBruna A.A., Hajjar D.P., et al. Transplantation of cryopreserved cultured epidermal allografts. J Trauma 1996, 40:743-750.
36. Woodley D.T., Peterson H.D., Herzog S.R., et al. Burn wounds resurfaced by cultured epidermal autografts show abnormal reconstitution of anchoring fibrils. JAMA 1988, 259:2566-2571.
37. Wainwright D.J. Use of an acellular allograft dermal matrix (AlloDerm) in the management of full-thickness burns. Burns 1995, 21:243-248.
38. Supp D.M., Boyce S.T. Engineered skin substitutes: practices and potentials. Clin Dermatol 2005, 23:403-412.
39. Kolokol'chikova E.G., Budkevich L.I., Bobrovnikov A.E., et al. Morphological changes in burn wounds after transplantation of allogenic fibroblasts. Bull Exp Biol Med 2001, 131:89-93.
40. Strande L.F., Foley S.T., Doolin E.J., et al. In vitro bioartificial skin culture model of tissue rejection and inflammatory/immune mechanisms. Transplant Proc 1997, 29:2118-2119.
41. Clark R.A., Ghosh K., Tonnesen M.G. Tissue engineering for cutaneous wounds. J Invest Dermatol 2007, 127:1018-1029.
42. Campoccia D., Doherty P., Radice M., et al. Semisynthetic resorbable materials from hyaluronan esterification. Biomaterials 1998, 19:2101-2127.
43. Caravaggi C., De Giglio R., Pritelli C., et al. HYAFF 11-based autologous dermal and epidermal grafts in the treatment of noninfected diabetic plantar and dorsal foot ulcers: a prospective, multicenter, controlled, randomized clinical trial. Diab Care 2003, 26:2853-2859.
44. Uccioli L. A clinical investigation on the characteristics and outcomes of treating chronic lower extremity wounds using the TissueTech Autograft System. Int J Low Extrem Wounds 2003, 2:140-151.
45. Myers S.R., Grady J., Soranzo C., et al. A hyaluronic acid membrane delivery system for cultured keratinocytes: clinical "take" rates in the porcine kerato-dermal model. J Burn Care Rehabil 1997, 18:214-222.
46. Nomi M., Atala A., Coppi P.D., et al. Principals of neovascularization for tissue engineering. Mol Aspects Med 2002, 23:463-483.
47. Eppler S.M., Combs D.L., Henry T.D., et al. A target-mediated model to describe the pharmacokinetics and hemodynamic effects of recombinant human vascular endothelial growth factor in humans. Clin Pharmacol Ther 2002, 72:20-32.
48. George M.L., Eccles S.A., Tutton M.G., et al. Correlation of plasma and serum vascular endothelial growth factor levels with platelet count in colorectal cancer: clinical evidence of platelet scavenging?. Clin Cancer Res 2000, 6:3147-3152.
49. Richardson T.P., Peters M.C., Ennett A.B., et al. Polymeric system for dual growth factor delivery. Nat Biotechnol 2001, 19:1029-1034.
50. Tremblay P.L., Hudon V., Berthod F., et al. Inosculation of tissue-engineered capillaries with the host's vasculature in a reconstructed skin transplanted on mice. American journal of transplantation: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2005, 5:1002-1010.
51. Swope V.B., Supp A.P., Cornelius J.R., et al. Regulation of pigmentation in cultured skin substitutes by cytometric sorting of melanocytes and keratinocytes. J Invest Dermatol 1997, 109:289-295.
52. Abdel-Malek Z.A. Endocrine factors as effectors of integumental pigmentation. Dermatol Clin 1988, 6:175-183.
53. Nordlund J.J., Abdel-Malek Z.A., Boissy R.E., et al. Pigment cell biology: an historical review. J Invest Dermatol 1989, 92:53S-60S.
54. Rogers G., Martinet N., Steinert P., et al. Cultivation of murine hair follicles as organoids in a collagen matrix. J Invest Dermatol 1987, 89:369-379.
55. Weinberg W.C., Brown P.D., Stetler-Stevenson W.G., et al. Growth factors specifically alter hair follicle cell proliferation and collagenolytic activity alone or in combination. Differentiation 1990, 45:168-178.
56. Philpott M.P., Green M.R., Kealey T. Human hair growth in vitro. J Cell Sci 1990, 97(Pt 3):463-471.
57. Huang Z., Yang J., Luo G., et al. Embryonic porcine skin precursors can successfully develop into integrated skin without teratoma formation posttransplantation in nude mouse model. PLoS ONE 2010, 5:e8717.
58. Ohyama M. Hair follicle bulge: a fascinating reservoir of epithelial stem cells. J Dermatol Sci 2007, 46:81-89.
59. Taylor G., Lehrer M.S., Jensen P.J., et al. Involvement of follicular stem cells in forming not only the follicle but also the epidermis. Cell 2000, 102:451-461.
60. Roh C., Lyle S. Cutaneous stem cells and wound healing. Pediatr Res 2006, 59:100R-103R.
61. Huang S., Xu Y., Wu C., et al. In vitro constitution and in vivo implantation of engineered skin constructs with sweat glands. Biomaterials 2010, 31:5520-5525.
62. Green H. The birth of therapy with cultured cells. BioEssays 2008, 30:897-903.
63. Sun T., Jackson S., Haycock J.W., et al. Culture of skin cells in 3D rather than 2D improves their ability to survive exposure to cytotoxic agents. J Biotechnol 2006, 122:372-381.
64. Robinson M.K., Osborne R., Perkins M.A. Strategies for the assessment of acute skin irritation potential. J Pharmacol Toxicol Meth 1999, 42:1-9.
65. Asselineau D., Bernard B., Bailly C., et al. Human epidermis reconstructed by culture: is it "normal"?. J Investig Dermatol 1986, 86:181-186.
66. Johnson E., Meunier S., Roy C., et al. Serial cultivation of normal human keratinocytes: a defined system for studying the regulation of growth and differentiation. In Vitro Cell Dev Biol 1992, 28:429-435.
67. Boehnke K., Mirancea N., Pavesio A., et al. Effects of fibroblasts and microenvironment on epidermal regeneration and tissue function in long-term skin equivalents. Eur J Cell Biol 2007, 86:731-746.
68. El-Ghalbzouri A., Gibbs S., Lamme E., et al. Effect of fibroblasts on epidermal regeneration. Br J Dermatol 2002, 147:230-243.
69. Xie Y., Rizzi S.C., Dawson R., et al. Development of a three-dimensional human skin equivalent wound model for investigating novel wound healing therapies. Tissue Eng C Meth 2010, 16:1111-1123.
70. Roguet R. Use of skin cell cultures for in vitro assessment of corrosion and cutaneous irritancy. Cell Biol Toxicol 1999, 15:63-75.
71. Welss T., Basketter D.A., Schroder K.R. In vitro skin irritation: facts and future. State of the art review of mechanisms and models. Toxicol In Vitro 2004, 18:231-243.
72. Draize J., Woodard G., Calvery H. Methods for the study of irritation and toxicity of substances applied topically to the skin and mucous membranes. J Pharmacol Exp Ther 1944, 82:377-390.
73. Campbell R.L., Bruce R.D. Direct comparison of rabbit and human primary skin irritation responses to isopropylmyristate. Toxicol Appl Pharmacol 1981, 563:555-563.
74. Phillips L., et al. A comparison of rabbit and human skin response to certain irritants. Toxicol Appl Pharmacol 1972, 21:369-382.
75. EU, Seventh Amendment to the EU Cosmetics Directive 76/768/EEC. In: The European Parliament and the Council of the European Union (Ed.), Brussels, 2003.
76. Becker R.A., Borgert C.J., Webb S., et al. Report of an ISRTP workshop: progress and barriers to incorporating alternative toxicological methods in the U.S. Regul Toxicol Pharmacol 2006, 46:18-22.
77. EU, Regulation (EC) No 1907/2006, in: E.P.A.T.C.O.T.E. UNION (Ed.), Official Journal of the European Union; 2006. p. L 396/391.
78. Kuroyanagi Y., Kubo K., Matsui H., et al. Establishment of banking system for allogeneic cultured dermal substitute. Artif Organs 2004, 28:13-21.
79. Oliver G.J., Pemberton M.a., Rhodes C. An in vitro model for identifying skin-corrosive chemicals. I. Initial validation. Toxicol In Vitro 1988, 2:7-17.
80. Scala R., Fentem J., Chen J., et al. Corrositex®: an in vitro test method for assessing dermal corrosivity potential of chemicals 1999.
81. Stobbe J.L., Drake K.D., Maier K.J. Comparison of in vivo (Draize method) and in vitro (Corrositex assay) dermal corrosion values for selected industrial chemicals. Int J Toxicol 2003, 22:99.
82. Perkins M.a., Osborne R., Johnson G.R. Development of an in vitro method for skin corrosion testing. Fundam Appl Toxicol 1996, 31:9-18.
83. Fentem J., Archer G., Balls M., et al. The ECVAM international validation study on in vitro tests for skin corrosivity. 2. Results and evaluation by the Management Team. Toxicol in Vitro 1998, 12:483-524.
84. Kandárová H., Liebsch M., Spielmann H., et al. Assessment of the human epidermis model SkinEthic RHE for in vitro skin corrosion testing of chemicals according to new OECD TG 431. Toxicol In Vitro 2006, 20:547-559.
85. Kidd D.A., Johnson M., Clements J. Development of an in vitro corrosion/irritation prediction assay using the EpiDerm skin model. Toxicol In Vitro 2007, 21:1292-1297.
86. ECVAM, Statement on the application of the EpiDermTM human skin model for skin corrosivity testing, in, 2000.
87. ECVAM, Statement on the application of the SkinEthicTM human skin model for skin corrosivity testing, in, 2006.
88. ECVAM, ESAC statement on the scientific validity of an in-vitro test method for skin corrosivity testing, in, 2009.
89. Perkins M.A., Osborne R., Rana F.R., et al. Comparison of in vitro and in vivo human skin responses to consumer products and ingredients with a range of irritancy potential. Toxicol Sci 1999, 48:218-229.
90. Coquette A. Analysis of interleukin-1α (IL-1α) and interleukin-8 (IL-8) expression and release in in vitro reconstructed human epidermis for the prediction of in vivo skin irritation and/or sensitization. Toxicol In Vitro 2003, 17:311-321.
91. Shanmugasundaram N., Ravikumar T., Babu M. Comparative physico-chemical and in vitro properties of fibrillated collagen scaffolds from different sources. J Biomater Appl 2004, 18:247-264.
92. Ohtani T., Okamoto K., Kaminaka C., et al. Digital gangrene associated with idiopathic hypereosinophilia: treatment with allogeneic cultured dermal substitute (CDS). Eur J Dermatol 2004, 14:168-171.
93. Eskes C., Cole T., Hoffmann S., et al. The ECVAM international validation study on in vitro tests for acute skin irritation: selection of test chemicals. Altern Lab Anim 2007, 35:603-619.
94. Spielmann H., Hoffmann S., Liebsch M., et al. The ECVAM international validation study on in vitro tests for acute skin irritation: report on the validity of the EPISKIN and EpiDerm assays and on the Skin Integrity Function Test. Altern Lab Anim 2007, 35:559-601.
95. Gabbanini S., Lucchi E., Carli M., et al. In vitro evaluation of the permeation through reconstructed human epidermis of essentials oils from cosmetic formulations. J Pharm Biomed Anal 2009, 50:370-376.
96. Jager MD, Groenink W, Spek JVD, et al. Preparation and characterization of a stratum corneum substitute for in vitro percutaneous penetration studies, 1758 (2006) 636-644.
97. Gysler A., Kleuser B., Sippl W., et al. Skin penetration and metabolism of topical glucocorticoids in reconstructed epidermis and in excised human skin. Pharm Res 1999, 16:1386-1391.
98. Ackermann K., Lombardi Borgia S., Korting H., et al. The Phenion® full-thickness skin model for percutaneous absorption testing. Skin Pharmacol Physiol 2009, 23:105-112.
99. Bouwstra J.A., Ponec M. The skin barrier in healthy and diseased state. Wide Angle Q. J. Film Hist. Theory Criticism Pract 2006, 1758:2080-2095.
100. Scheuplein R.J. Mechanism of percutaneous absorption. II. Transient diffusion and the relative importance of various routes of skin penetration. J Invest Dermatol 1967, 48:79-88.
101. Kao J., Hall J., Helman G. In vitro percutaneous absorption in mouse skin: influence of skin appendages. Toxicol Appl Pharmacol 1988, 94:93-103.
102. Illel B., Schaefer H., Wepierre J., et al. Follicles play an important role in percutaneous absorption. J Pharm Sci 1991, 80:424-427.
103. Michel M., L'Heureux N., Pouliot R., et al. Characterization of a new tissue-engineered human skin equivalent with hair. In Vitro Cell Dev Biol Anim 1999, 35:318-326.
104. Brenner M., Hearing V.J. The protective role of melanin against UV damage in human skin. Photochem Photobiol 2008, 84:539-549.
105. Chen G., Sato T., Ohgushi H., et al. Culturing of skin fibroblasts in a thin PLGA-collagen hybrid mesh. Biomaterials 2005, 26:2559-2566.
106. Bertaux B., Morliere P., Moreno G., et al. Growth of melanocytes in a skin equivalent model in vitro. Br J Dermatol 1988, 119:503-512.
107. Bessou S., Surléve-Bazeille J.E., Sorbier E., et al. Ex vivo reconstruction of the epidermis with melanocytes and the influence of UVB. Pigment Cell 1995, 8:241-249.
108. Topol B.M., Haimes H.B., Dubertret L., et al. Transfer of melanosomes in a skin equivalent model in vitro. J Invest Dermatol 1986, 87:642-647.
109. Bernerd F., Asselineau D. Successive alteration and recovery of epidermal differentiation and morphogenesis after specific UVB-damages in skin reconstructed in vitro. Dev Biol 1997, 183:123-138.
110. Maresca V., Flori E., Briganti S., et al. UVA-induced modification of catalase charge properties in the epidermis is correlated with the skin phototype. J Investig Dermatol 2006, 126:182-190.
111. Garibyan L., Fisher D.E. How sunlight causes melanoma. Curr Oncol Rep 2010, 12:319-326.
112. Bernerd F., Asselineau D. An organotypic model of skin to study photodamage and photoprotection in vitro. J Am Acad Dermatol 2008, 58:S155-S159.
113. Leliãr̈vre D., Justine P., Christiaens F., et al. The episkin phototoxicity assay (EPA): development of an in vitro tiered strategy using 17 reference chemicals to predict phototoxic potency. Toxicol. In Vitro 2007, 21:977-995.
114. Nolte S.V., Xu W., Rennekampff H.-O., et al. Diversity of fibroblasts-a review on implications for skin tissue engineering. Cells Tissues Organs 2008, 187:165-176.
115. Freshney R.I. Culture of Animal Cells. A Manual of Basic Techniques 2000, Wiley & Liss, New York.
116. Falanga V., Isaacs C., Paquette D., et al. Wounding of bioengineered skin: cellular and molecular aspects after injury. J Investig Dermatol 2002, 119:653-660.
117. Andriani F., Margulis A., Lin N., et al. Analysis of microenvironmental factors contributing to basement membrane assembly and normalized epidermal phenotype. J Investig Dermatol 2003, 120:923-931.
118. Lee D.-Y., Cho K.-H. The effects of epidermal keratinocytes and dermal fibroblasts on the formation of cutaneous basement membrane in three-dimensional culture systems. Arch Dermatol Res 2005, 296:296-302.
119. Maas-Szabowski N., Shimotoyodome A., Fusenig N.E. Keratinocyte growth regulation in fibroblast cocultures via a double paracrine mechanism. J Cell Sci 1999, 112(Pt 1):1843-1853.
120. Maas-Szabowski N., Stark H.J., Fusenig N.E. Keratinocyte growth regulation in defined organotypic cultures through IL-1-induced keratinocyte growth factor expression in resting fibroblasts. J Investig Dermatol 2000, 114:1075-1084.
121. Coulomb B., Dubertet L., Merrill C., et al. The collagen lattice: a model for studying the physiology, biosynthetic function and pharmacology of the skin. Br J Dermatol 1984, 111(Suppl 27):83-87.
122. Bell E., Ehrlich H.P., Buttle D.J., et al. Living tissue formed in vitro and accepted as skin-equivalent tissue of full thickness. Science (New York, NY) 1981, 211:1052-1054.
123. Sun T., Jackson S., Haycock J.W., et al. Culture of skin cells in 3D rather than 2D improves their ability to survive exposure to cytotoxic agents. J Biotechnol 2006, 122:372-381.
124. Bell E., Sher S., Hull B., et al. The reconstitution of living skin. J Investig 1983, 81(1 Suppl):2s-10s.
125. TM: an alternative dermal irritation model. In Vitro Toxicol 1992, 5:177-189.
126. Parenteau N.L., Bilbo P., Nolte C.J., et al. The organotypic culture of human skin keratinocytes and fibroblasts to achieve form and function. Cytotechnology 1992, 9:163-171.
127. Stark H.-J., Boehnke K., Mirancea N., et al. Epidermal homeostasis in long-term scaffold-enforced skin equivalents. J Investig Dermatol Symp Proc 2006, 11:93-105.
128. Sahuc F., Nakazawa K., Berthod F. Mesenchymal-epithelial interactions regulate gene expression of type V11 collagen and kalinin in keratinocytes and dermal-epidermal junction formation in a skin equivalent model. Wound Repair Regen 1996, 4:93-102.
129. Lindberg K., Badylak S.F. Porcine small intestinal submucosa (SIS): a bioscaffold supporting in vitro primary human epidermal cell differentiation and synthesis of basement membrane proteins. Burns 2001, 27:254-266.
130. Ng K.W., Hutmacher D.W. Reduced contraction of skin equivalent engineered using cell sheets cultured in 3D matrices. Biomaterials 2006, 27:4591-4598.
131. Bruin P., Smedinga J., Pennings A.J., et al. Biodegradable lysine diisocyanate-based poly(glycolide-co-epsilon-caprolactone)-urethane network in artificial skin. Biomaterials 1990, 11:291-295.
132. Ng K.W., Khor H.L., Hutmacher D.W. In vitro characterization of natural and synthetic dermal matrices cultured with human dermal fibroblasts. Biomaterials 2004, 25:2807-2818.
133. Dai N.T., Yeh M.K., Chiang C.H., et al. Human single-donor composite skin substitutes based on collagen and polycaprolactone copolymer. Biochem Biophys Res Commun 2009, 386:21-25.
134. Graf R., Kock M., Bock A., et al. Lipophilic prodrugs of amino acids and vitamin E as osmolytes for the compensation of hyperosmotic stress in human keratinocytes. Exp Dermatol 2009, 18:370-377.
135. Williams I.R., Kupper T.S. Immunity at the surface: homeostatic mechanisms of the skin immune system. Life Sci 1996, 58:1485-1507.
136. Régnier M., Staquet M.J., Schmitt D., et al. Integration of Langerhans cells into a pigmented reconstructed human epidermis. The Journal of investigative dermatology 1997, 510-512.
137. Fransson J., Heffler L.C., Tengvall Linder M., et al. Culture of human epidermal Langerhans cells in a skin equivalent. Br J Dermatol 1998, 139:598-604.
138. Boyce S.T. Cultured skin substitutes: a review. Tissue Eng 1996, 2:255-266.
139. Koblizek T.I., Weiss C., Yancopoulos G.D., et al. Angiopoietin-1 induces sprouting angiogenesis in vitro. Curr Biol 1998, 8:529-532.
140. Nör J.E., Christensen J., Mooney D.J., et al. Vascular endothelial growth factor (VEGF)-mediated angiogenesis is associated with enhanced endothelial cell survival and induction of Bcl-2 expression. Am J Pathol 1999, 154:375-384.
141. Trochon V., Li H., Vasse M., et al. Endothelial metalloprotease-disintegrin protein (ADAM) is implicated in angiogenesis in vitro. Angiogenesis 1998, 2:277-285.
142. Bach T.L., Barsigian C., Yaen C.H., et al. Endothelial cell VE-cadherin functions as a receptor for the beta15-42 sequence of fibrin. J Biol Chem 1998, 273:30719-30728.
143. Bayless K.J., Salazar R., Davis G.E. RGD-dependent vacuolation and lumen formation observed during endothelial cell morphogenesis in three-dimensional fibrin matrices involves the alpha(v)beta(3) and alpha(5)beta(1) integrins. Am J Pathol 2000, 156:1673-1683.
144. Black A.F., Berthod F., L'Heureux N., et al. In vitro reconstruction of a human capillary-like network in a tissue-engineered skin equivalent. FASEB J 1998, 12:1331-1340.
145. Donovan D., Brown N.J., Bishop E.T., et al. Comparison of three in vitro human 'angiogenesis' assays with capillaries formed in vivo. Angiogenesis 2001, 4:113-121.
146. Ponec M., El Ghalbzouri A., Dijkman R., et al. Endothelial network formed with human dermal microvascular endothelial cells in autologous multicellular skin substitutes. Angiogenesis 2004, 7:295-305.
147. Dewey C.F., Bussolari S.R., Gimbrone M.A., et al. The dynamic response of vascular endothelial cells to fluid shear stress. J Biomech Eng 1981, 103:177-185.
148. Bandarchi B., Ma L., Navab R., et al. From melanocyte to metastatic malignant melanoma. Dermatol. Res. Pract 2010, Article ID 583748, 8 pages, doi:10.1155/2010/583748.
149. Bowcock A.M., Krueger J.G. Getting under the skin: the immunogenetics of psoriasis. Nat Rev Immunol 2005, 5:699-711.
150. Danilenko D.M. Review paper: preclinical models of psoriasis. Vet Pathol 2008, 45:563-575.
151. Saiag P., Coulomb B., Lebreton C., et al. Psoriatic fibroblasts induce hyperproliferation of normal keratinocytes in a skin equivalent model in vitro. Science 1985, 230:669-672.
152. Fransson J., Hammar H., Emilson A., et al. Proliferation and interferon-γ receptor expression in psoriatic and healthy keratinocytes are influenced by interactions between keratinocytes and fibroblasts in a skin equivalent model. Arch Dermatol Res 1995, 287:517-523.
153. Konstantinova N.V., Duong D.M., Remenyik E., et al. Interleukin-8 is induced in skin equivalents and is highest in those derived from psoriatic fibroblasts. J Invest Dermatol 1996, 107:615-621.
154. Baker B.S., Griffiths C.E., Lambert S., et al. The effects of cyclosporin A on T lymphocyte and dendritic cell sub-populations in psoriasis. Br J Dermatol 1987, 116:503-510.
155. Prinz J., Braun-Falco O., Meurer M., et al. Chimaeric CD4 monoclonal antibody in treatment of generalised pustular psoriasis. Lancet 1991, 320-321.
156. Gottlieb S., Gilleaudeau P., Johnson R., et al. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med 1995, 1:442-447.
157. Jean J., Lapointe M., Soucy J., et al. Development of an in vitro psoriatic skin model by tissue engineering. J Dermatol Sci 2009, 53:19-25.
158. Barker C.L., McHale M.T., Gillies A.K., et al. The development and characterization of an in vitro model of psoriasis. J Investig Dermatol 2004, 123:892-901.
159. Harrison C.A., Layton C.M., Hau Z., et al. Transglutaminase inhibitors induce hyperproliferation and parakeratosis in tissue-engineered skin. Br J Dermatol 2007, 156:247-257.
160. Tjabringa G., Bergers M., van Rens D., et al. Development and validation of human psoriatic skin equivalents. Am J Pathol 2008, 173:815-823.
161. Kalish R.S., Simon M., Harrington R., et al. Skin equivalent and natural killer cells: a new model for psoriasis and GVHD. J Investig Dermatol 2009, 129:773-776.
162. Uong A., Zon L.I. Melanocytes in development and cancer. J Cell Physiol 2010, 222:38-41.
163. Hsu M.-Y., Meier F., Herlyn M. Melanoma development and progression: a conspiracy between tumor and host. Differentiation 2002, 70:522-536.
164. Shih I.M., Elder D.E., Hsu M.Y., et al. Regulation of Mel-CAM/MUC18 expression on melanocytes of different stages of tumor progression by normal keratinocytes. Am J Pathol 1994, 145:837-845.
165. Walles T., Weimer M., Linke K., et al. The potential of bioartificial tissues in oncology research and treatment. Onkologie 2007, 30:388-394.
166. Meier F., Nesbit M., Hsu M.Y., et al. Human melanoma progression in skin reconstructs: biological significance of bFGF. Am J Pathol 2000, 156:193-200.
167. Eves P., Haycock J., Layton C., et al. Anti-inflammatory and anti-invasive effects of alpha-melanocyte-stimulating hormone in human melanoma cells. Br J Cancer 2003, 89:2004-2015.
168. Eves P., Katerinaki E., Simpson C., et al. Melanoma invasion in reconstructed human skin is influenced by skin cells-investigation of the role of proteolytic enzymes. Clin Exp Metastasis 2003, 20:685-700.
169. Van Kilsdonk J.W.J., Bergers M., Van Kempen L.C.L.T., et al. Keratinocytes drive melanoma invasion in a reconstructed skin model. Melanoma Res 2010, 20:372.
170. Gaggioli C., Robert G., Bertolotto C., et al. Tumor-derived fibronectin is involved in melanoma cell invasion and regulated by V600E B-Raf signaling pathway. J Investig Dermatol 2007, 127:400-410.
171. Grindon C., Combes R., Cronin M.T., et al. A review of the status of alternative approaches to animal testing and the development of integrated testing strategies for assessing the toxicity of chemicals under REACH-a summary of a DEFRA-funded project conducted by Liverpool John Moores University. Altern Lab Anim 2006, 34:149-458.
172. Meier F., Busch S., Lasithiotakis K., et al. Combined targeting of MAPK and AKT signalling pathways is a promising strategy for melanoma treatment. Br J Dermatol 2007, 156:1204-1213.
173. Folkman J. What is the evidence that tumors are angiogenesis dependent?. J Natl Cancer Inst 1990, 82:4-6.
174. Liotta L.A., Kleinerman J., Saidel G.M. Quantitative relationships of intravascular tumor cells, tumor vessels, and pulmonary metastases following tumor implantation. Cancer Res 1974, 34:997-1004.
175. Weiss S.J. Tissue destruction by neutrophils. N Engl J Med 1989, 320:365-376.
176. Martin P., Leibovich S.J. Inflammatory cells during wound repair: the good, the bad and the ugly. Trends Cell Biol 2005, 15:599-607.
177. Leibovich S.J., Ross R. The role of the macrophage in wound repair. A study with hydrocortisone and antimacrophage serum. Am J Pathol 1975, 78:71-100.
178. Polverini P.J., Cotran P.S., Gimbrone M.A., et al. Activated macrophages induce vascular proliferation. Nature 1977, 269:804-806.
179. Eming S.A., Brachvogel B., Odorisio T., et al. Regulation of angiogenesis: wound healing as a model. Prog Histochem Cytochem 2007, 42:115-170.
180. Coolen N.A., Vlig M., van den Bogaerdt A.J., et al. Development of an in vitro burn wound model. Wound Repair Regen 2008, 16:559-567.
181. Schreier T., Degen E., Baschong W. Fibroblast migration and proliferation during in vitro wound healing. A quantitative comparison between various growth factors and a low molecular weight blood dialysate used in the clinic to normalize impaired wound healing. Res Exp Med (Berl) 1993, 193:195-205.
182. Kratz G. Modeling of wound healing processes in human skin using tissue culture. Microsc Res Tech 1998, 42:345-350.
183. Emanuelsson P., Kratz G. Characterization of a new in vitro burn wound model. Burns 1997, 23:32-36.
184. Vaughan M.B., Ramirez R.D., Brown S.A., et al. A reproducible laser-wounded skin equivalent model to study the effects of aging in vitro. Rejuvenation Res 2004, 7:99-110.
185. Mishra N.N., Prasad T., Sharma N., et al. Pathogenicity and drug resistance in Candida albicans and other yeast species. A review. Acta Microbiol Immunol Hung 2007, 54:201-235.
186. Green C.B. RT-PCR detection of Candida albicans ALS gene expression in the reconstituted human epithelium (RHE) model of oral candidiasis and in model biofilms. Microbiology 2004, 150:267-275.
187. Schaller M., Preidel H., Januschke E., et al. Light and electron microscopic findings in a model of human cutaneous candidosis based on reconstructed human epidermis following the topical application of different econazole formulations. J Drug Target 1999, 6:361-372.
188. Korting H.C., Patzak U., Schaller M., et al. A model of human cutaneous candidosis based on reconstructed human epidermis for the light and electron microscopic study of pathogenesis and treatment. J Infect 1998, 36:259-267.
189. Schaller M., Mailhammer R., Korting H.C. Cytokine expression induced by Candida albicans in a model of cutaneous candidosis based on reconstituted human epidermis. J Med Microbiol 2002, 51:672-676.
190. Schaller M., Schackert C., Korting H.C., et al. Invasion of Candida albicans correlates with expression of secreted aspartic proteinases during experimental infection of human epidermis. J Investig Dermatol 2000, 114:712-717.
191. Korting H.C., Schaller M., Eder G., et al. Effects of the human immunodeficiency virus (HIV) proteinase inhibitors saquinavir and indinavir on in vitro activities of secreted aspartyl proteinases of Candida albicans isolates from HIV-infected patients. Antimicrob Agents Chemother 1999, 43:2038-2042.
192. Andrei G., Duraffour S., Van den Oord J., et al. Epithelial raft cultures for investigations of virus growth, pathogenesis and efficacy of antiviral agents. Antivir Res 2010, 85:431-449.
193. Riediger C., Sauer P., Matevossian E., et al. Herpes simplex virus sepsis and acute liver failure. Clin Transplant 2009, 23:37-41.
194. Tabbara K.F., Al Balushi N. Topical ganciclovir in the treatment of acute herpetic keratitis. Clin. Ophthalmol (Auckland, NZ) 2010, 4:905-912.
195. Stevens J.G., Cook M.L. Latent herpes simplex virus in spinal ganglia of mice. Science 1971, 173:843-845.
196. Visalli R.J., Courtney R.J., Meyers C. Infection and replication of herpes simplex virus type 1 in an organotypic epithelial culture system. Virology 1997, 230:236-243.
197. Hukkanen V., Mikola H., Nykänen M., et al. Herpes simplex virus type 1 infection has two separate modes of spread in three-dimensional keratinocyte culture. J Gen Virol 1999, 80(Pt 8):2149-2155.
198. Syrjänen S., Mikola H., Nykänen M., et al. In vitro establishment of lytic and nonproductive infection by herpes simplex virus type 1 in three-dimensional keratinocyte culture. J Virol 1996, 70:6524-6528.
199. Andrei G., Oord J.V.D., Fiten P., et al. Organotypic epithelial raft cultures as a model for evaluating compounds against alphaherpesviruses. Society 2005, 49:4671-4680.
200. Penfold M.E., Armati P., Cunningham A.L. Axonal transport of herpes simplex virions to epidermal cells: evidence for a specialized mode of virus transport and assembly. Proc Natl Acad Sci USA 1994, 91:6529-6533.
201. Tfayli A., Piot O., Draux F., et al. Molecular characterization of reconstructed skin model by Raman microspectroscopy: comparison with excised human skin. Biopolymers 2007, 87:261-274.
202. Allen-Hoffmann B.L., Schlosser S.J., Ivarie C.A.R., et al. Normal growth and differentiation in a spontaneously immortalized near-diploid human keratinocyte cell line, NIKS. Differentiation 2000, 444-455.
203. Marston W.A., Hanft J., Norwood P., et al. The efficacy and safety of Dermagraft in improving the healing of chronic diabetic foot ulcers: results of a prospective randomized trial. Diab Care 2003, 26:1701-1705.
204. Dieterich C., Schandar M., Noll M., et al. In vitro reconstructed human epithelia reveal contributions of Candida albicans EFG1 and CPH1 to adhesion and invasion. Microbiology 2002 Feb, 148(Pt 2):497-506.